Non-Alcoholic Steatohepatitis (NASH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Nonalcoholic fatty liver disease (NAFLD) is characterized by fat accumulation within the liver. A more severe variant of NAFLD is known as nonalcoholic steatohepatitis (NASH), which leads to liver inflammation and damage. NASH typically develops in individuals who are overweight or obese have diabetes, high cholesterol, or elevated triglyceride levels. Nevertheless, some individuals may develop NASH even without these risk factors. NASH progresses through three distinct stages:

 

Stage 1, called compensated cirrhosis or NASH without fibrosis, denotes a stage where the liver's function remains intact despite some compromise. The liver exhibits slight enlargement, inflammation, and fat accumulation exceeding 5% (steatosis).

Stage 2, known as NASH with fibrosis, encompasses the features of Stage 1 and involves the development of liver scarring (fibrosis). This fibrosis stage has four degrees, with Stage 2 corresponding to fibrosis levels 1 to 3.

Stage 3 signifies the severe stage of NASH, where extensive liver cirrhosis or liver cancer may occur. At this point, the only viable treatment option is a liver transplant. The damage inflicted by NASH poses a significant risk to the cardiovascular system, as it releases harmful free radicals into the bloodstream.

The progression of NASH is driven by factors such as obesity, insulin resistance, and type 2 diabetes mellitus (non-insulin-dependent), leading to increased fatty acid flux within the liver and hypertension and dyslipidemia. Sedentary lifestyles, poor dietary habits, and unhealthy eating patterns contribute to the prevalence of obesity and insulin resistance, exacerbating liver dysfunction. Additional risk factors for NASH include a poor diet, polycystic ovarian disease (PCOD), hypothyroidism, high cholesterol, obstructive sleep apnea, small bowel bacterial overgrowth, and high triglyceride levels. NASH can also have a hereditary component, and individuals with family members affected by NASH or NAFLD are at a higher risk. The pathogenesis of NASH is often described using a "two-hit" hypothesis, where the initial "hit" leads to steatosis and subsequent progression to steatohepatitis. NASH results from a combination of factors, including oxidative stress (caused by free radicals during fatty acid oxidation), the release of tumor necrosis factor-alpha (a cytokine), immune factors, direct lipotoxicity, gut-derived endotoxin, and endoplasmic reticulum stress. Over an average follow-up period of 13.7 years, NASH has been associated with a tenfold increased risk of liver-related mortality and a doubling cardiovascular risk. Currently, there is no approved therapy for NASH. The typical age range for NASH patients is between 40 and 50 years, with the development of NASH-related cirrhosis occurring between 50 and 60, even without alcohol consumption. Childhood obesity is becoming increasingly prevalent, indicating that NASH now affects younger individuals. NASH is often asymptomatic in its early stages, earning it the moniker of a "silent disease."

 

It is more prevalent among women than men, and many individuals may have NASH for years before experiencing noticeable symptoms. NASH is one of the primary causes of cirrhosis in adults in the United States, with up to 25% of adults with NASH ultimately developing cirrhosis.

 

Thelansis’s “Non-Alcoholic Steatohepatitis (NASH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Alcoholic Steatohepatitis (NASH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Non-Alcoholic Steatohepatitis (NASH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-Alcoholic Steatohepatitis (NASH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Alcoholic Steatohepatitis (NASH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Non-Alcoholic Steatohepatitis (NASH), Non-Alcoholic Steatohepatitis (NASH) market outlook, Non-Alcoholic Steatohepatitis (NASH) competitive landscape, Non-Alcoholic Steatohepatitis (NASH) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)